Frazier Life Sciences Management, L.P.
Q1 2022 13F-HR Holdings
Net value change ($000)
—
New positions
42
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ARQT | 162,443 | — |
| PHAT | 79,311 | — |
| MIRM | 78,543 | — |
| Sierra Oncology, Inc. | 75,067 | — |
| KRYS | 57,640 | — |
| Imago BioSciences, Inc. | 57,256 | — |
| PCVX | 55,776 | — |
| SNDX | 55,536 | — |
| CHINOOK THERAPEUTICS, INC. | 44,369 | — |
| IVERIC bio, Inc. | 40,755 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|